• SIGN IN
  • GET HELP
  •  


    Support provided for the following courses by the: Anticoagulation Forum

    Faculty:
      Dominick Angiolillo, MD PHD, FACC, FESC, FSCAI
      Geoffrey Barnes, M.D., M.Sc., FACC, FAHA, FSVM, RPVI
      Renato Lopes, MD, MHS, PhD
      Roxana Mehran, MD, FACC, FACP, FAHA, FCCP, FESC, MSCAI

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Summarize current 2019 ACC/AHA/HRS Atrial Fibrillation guideline recommendations for patients with an indication for oral anticoagulation undergoing PCI
      2. Describe the AFIRE trial study design and interpret primary endpoints and conclusions
      3. Recognize the AFIRE trial strengths and limitations
      4. Discuss how the AFIRE trial findings can be applied to real-world patient populations
    • Nurse
      1. Summarize current 2019 ACC/AHA/HRS Atrial Fibrillation guideline recommendations for patients with an indication for oral anticoagulation undergoing PCI
      2. Describe the AFIRE trial study design and interpret primary endpoints and conclusions
      3. Recognize the AFIRE trial strengths and limitations
      4. Discuss how the AFIRE trial findings can be applied to real-world patient populations

    Faculty:
      Allison Burnett, PharmD, PHc, CACP
      Darren Triller, PharmD
      Tracy Minichiello, MD
      Scott Kaatz, DO, MSc, FACP, SFHM

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Recognize each of the seven Core Elements of Anticoagulation Stewardship
      2. Identify barriers to implementation of Anticoagulation Stewardship Programs
      3. Identify strategies to implement Anticoagulation Stewardship programs in hospitals and other care settings
    • Nurse
      1. Recognize each of the seven Core Elements of Anticoagulation Stewardship
      2. Identify barriers to implementation of Anticoagulation Stewardship Programs
      3. Identify strategies to implement Anticoagulation Stewardship programs in hospitals and other care settings

    Faculty:
      Geoffrey Barnes, M.D., M.Sc., FACC, FAHA, FSVM, RPVI
      Nathan Clark, PharmD, FCCP, BCPS
      James Douketis, MD

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Describe the periprocedural protocol and statistical analysis of the PAUSE Study
      2. Identify the results of the PAUSE Study for each DOAC cohort in regard to major bleeding and thrombosis rates
      3. Identify key patient populations not included in the PAUSE Study
      4. Recognize the implications of the PAUSE Study findings for the real-world surgical environment
    • Nurse
      1. Describe the periprocedural protocol and statistical analysis of the PAUSE Study
      2. Identify the results of the PAUSE Study for each DOAC cohort in regard to major bleeding and thrombosis rates
      3. Identify key patient populations not included in the PAUSE Study
      4. Recognize the implications of the PAUSE Study findings for the real-world surgical environment

    Faculty:
      Diane Wirth, ANP, CACP
      Christine Baumgartner, MD, MAS, FMH
      Margaret Fang, MD, MPH

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Identify patient populations in whom the risk of bridging likely outweighs the clinical benefits
      2. Identify appropriate possible strategies to implement shared decision-making involving patients, proceduralists, and other care providers
      3. Describe the current state of medical evidence regarding bridging for VTE Patients utilizing vitamin K antagonists who require invasive medical procedures
    • Nurse
      1. Identify appropriate possible strategies to implement shared decision-making involving patients, proceduralists, and other care providers
      2. Describe the current state of medical evidence regarding bridging for VTE Patients utilizing vitamin K antagonists who require invasive medical procedures
      3. Identify patient populations in whom the risk of bridging likely outweighs the clinical benefits

    Faculty:
      Adam Cuker, MD, MS, FACP
      Sara Vzaquex, PharmD, BCPS, CACP
      Allison Burnett, PharmD, PHc, CACP

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Identify appropriate expert guidance regarding when and how to administer reversal agents to users of DOACs
      2. Recognize strategies to support the effective management of reversal agents for DOACs
      3. Identify weaknesses in available evidence regarding currently available specific reversal agents for DOACs
    • Nurse
      1. Recognize strategies to support the effective management of reversal agents for DOACs
      2. Identify weaknesses in available evidence regarding currently available specific reversal agents for DOACs
      3. Identify appropriate expert guidance regarding when and how to administer reversal agents to users of DOACs

    Faculty:
      Adam Cuker, MD, MS, FACP
      Daniel Witt, PharmD, FCCP, BCPS
      Michael Streiff, MD, FACP

    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Recognize appropriate evidence-based recommendations regarding optimal use of anticoagulation therapy for patients with venous thromboembolism
      2. Identify an evidence-based algorithm for the diagnostic evaluation of patients with suspected heparin-induced thrombocytopenia (HIT)
      3. Recognize appropriate management of anticoagulation therapy during invasive procedures
      4. Identify non-heparin anticoagulant treatment options for patients with HIT
    • Nurse
      1. Recognize appropriate evidence-based recommendations regarding optimal use of anticoagulation therapy for patients with venous thromboembolism
      2. Identify an evidence-based algorithm for the diagnostic evaluation of patients with suspected heparin-induced thrombocytopenia (HIT)
      3. Identify non-heparin anticoagulant treatment options for patients with HIT
      4. Recognize appropriate management of anticoagulation therapy during invasive procedures

    Faculty:
      Marc Carrier, MD, MSc, FRCPC
      Diane Wirth, ANP, CACP


    Contact Hours:1.0
    Learning Objectives:
    • Pharmacist
      1. Recognize clinical and patient-related factors that increase the risk of adverse outcomes while treating cancer-associated VTE
      2. Describe the results of recent research involving DOACs in the treatment of cancer-associated VTE
      3. Identify specific circumstances in which medical evidence supports the preferential use of DOACs and parenteral anticoagulants
    • Nurse
      1. Identify specific circumstances in which medical evidence supports the preferential use of DOACs and parenteral anticoagulants
      2. Recognize clinical and patient-related factors that increase the risk of adverse outcomes while treating cancer-associated VTE
      3. Describe the results of recent research involving DOACs in the treatment of cancer-associated VTE